Tramadol acts as a weak reinforcer in the rat self-administration model, consistent with its low abuse liability in humans

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 3, 2010, Pages 279-286

  O'Connor, Eoin C ^a   Mead, Andy N ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Abuse potential; Morphine; Opioid; Reinforcement; Reinforcing efficacy; Remifentanil; Scheduling remifentanil

Indexed keywords

MORPHINE; REMIFENTANIL; TRAMADOL; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG EFFECT; DRUG RESPONSE; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RAT; REINFORCEMENT; TRAINING; AGONISTS; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; INSTRUMENTAL CONDITIONING; OPIATE ADDICTION; PSYCHOLOGY;

ANALGESICS, OPIOID; ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MORPHINE; OPIOID-RELATED DISORDERS; PIPERIDINES; RATS; RECEPTORS, OPIOID, MU; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION; TRAMADOL;

RATTUS; RODENTIA;

EID: 77954762744     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.018     Document Type: Article

References (55)

1. Arnold J.M., Roberts D.C. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 1997, 57:441-447.
2. Ator N.A., Griffiths R.R. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 2003, 70:S55-72.
3. Balster R.L. Drug abuse potential evaluation in animals. Br J Addict 1991, 86:1549-1558.
4. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003, 70:S13-40.
5. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 1989, 251:150-155.
6. Brady J.V., Griffiths R.R. Behavioral procedures for evaluating the relative abuse potential of CNS drugs in primates. Fed Proc 1976, 35:2245-2253.
7. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 2009, 105(Suppl 1):S14-25.
8. Colpaert F.C. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1999, 64:337-345.
9. EMEA. Guidline on the non-clinical investigation of the dependence potential of medicinal products. In: CHMP, editor: EMEA, 2006.
10. Emmett-Oglesby M.W., Mathis D.A., Moon R.T., Lal H. Animal models of drug withdrawal symptoms. Psychopharmacology (Berl) 1990, 101:292-309.
11. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 2006, 73:90-99.
12. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann NY Acad Sci 1999, 877:412-438.
13. Filip M., Wydra K., Inan S.Y., Dziedzicka-Wasylewska M., Przegalinski E. Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats. Eur J Pharmacol 2004, 498:143-151.
14. Gibson T.P. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996, 101:47S-53S.
15. Grasing K., Li N., He S., Parrish C., Delich J., Glowa J. A new progressive ratio schedule for support of morphine self-administration in opiate dependent rats. Psychopharmacology (Berl) 2003, 168:387-396.
16. Griffith J.D., Carranza J., Griffith C., Miller L.L. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983, 44:206-208.
17. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43:879-923.
18. Hoffmeister F. Progressive-ratio performance in the rhesus monkey maintained by opiate infusions. Psychopharmacology (Berl) 1979, 62:181-186.
19. Johanson C.E. The evaluation of the abuse liability of drugs. Drug Saf 1990, 5(Suppl 1):46-57.
20. Johanson C.E., Balster R.L. A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 1978, 30:43-54.
21. Katz J.L. Models of relative reinforcing efficacy of drugs and their predictive utility. Behav Pharmacol 1990, 1:283-301.
22. Katz J.L., Goldberg S.R. Preclinical assessment of abuse liability of drugs. Agents Actions 1988, 23:18-26.
23. Lamb R.J., Preston K.L., Schindler C.W., Meisch R.A., Davis F., Katz J.L., et al. The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 1991, 259:1165-1173.
24. Lau C.E., Sun L. The pharmacokinetic determinants of the frequency and pattern of intravenous cocaine self-administration in rats by pharmacokinetic modeling. Drug Metab Dispos 2002, 30:254-261.
25. Magalas Z., De Vry J., Tzschentke T.M. The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur J Pharmacol 2005, 528:103-109.
26. Marsch L.A., Bickel W.K., Badger G.J., Rathmell J.P., Swedberg M.D., Jonzon B., et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299:1056-1065.
27. Mead A.N., Stephens D.N. Involvement of AMPA receptor GluR2 subunits in stimulus-reward learning: evidence from glutamate receptor gria2 knock-out mice. J Neurosci 2003, 23:9500-9507.
28. Mead A.N., Stephens D.N. Selective disruption of stimulus-reward learning in glutamate receptor gria1 knock-out mice. J Neurosci 2003, 23:1041-1048.
29. Mead A.N., Brown G., Le Merrer J., Stephens D.N. Effects of deletion of gria1 or gria2 genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice. Psychopharmacology (Berl) 2005, 179:164-171.
30. Michelsen L.G., Hug C.C. The pharmacokinetics of remifentanil. J Clin Anesth 1996, 8:679-682.
31. Myrick H., Malcolm R., Taylor B., LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry 2004, 16:101-109.
32. Norman A.B., Tsibulsky V.L. The compulsion zone: a pharmacological theory of acquired cocaine self-administration. Brain Res 2006, 1116:143-152.
33. O'Connor E.C., Crombag H.S., Mead A.N., Stephens D.N. The mGluR5 antagonist MTEP Dissociates the Acquisition of Predictive and Incentive Motivational Properties of Reward-Paired Stimuli in Mice. Neuropsychopharmacology 2010, 35:1807-1817.
34. Panlilio L.V., Goldberg S.R. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction (Abingdon, England) 2007, 102:1863-1870.
35. Panlilio L.V., Schindler C.W. Self-administration of remifentanil, an ultra-short acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology (Berl) 2000, 150:61-66.
36. Parasrampuria R., Vuppugalla R., Elliott K., Mehvar R. Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. Chirality 2007, 19:190-196.
37. Ren Y.H., Zheng J.W. Influence of tramadol on morphine discriminative behavior in rats. Acta Pharmacol Sin 2000, 21:924-926.
38. Richardson N.R., Roberts D.C. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Meth 1996, 66:1-11.
39. Roberts D.C., Bennett S.A. Heroin self-administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 1993, 111:215-218.
40. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18:247-291.
41. Sanchis-Segura C., Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 2006, 11:2-38.
42. Solinas M., Panlilio L.V., Justinova Z., Yasar S., Goldberg S.R. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 2006, 1:1194-1206.
43. Sprague J.E., Leifheit M., Selken J., Milks M.M., Kinder D.H., Nichols D.E. In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse 2002, 43:118-121.
44. Stafford D., LeSage M.G., Glowa J.R. Progressive-ratio schedules of drug delivery in the analysis of drug self-administration: a review. Psychopharmacology (Berl) 1998, 139:169-184.
45. Stephens D.N., Duka T., Crombag H.S., Cunningham C.L., Heilig M., Crabbe J.C. Reward sensitivity: issues of measurement, and achieving consilience between human and animal phenotypes. Addict Biol 2010, 15:145-168.
46. Swedberg M.D., Shannon H.E., Nickel B., Goldberg S.R. Pharmacological mechanisms of action of flupirtine: a novel, centrally acting, nonopioid analgesic evaluated by its discriminative effects in the rat. J Pharmacol Exp Ther 1988, 246:1067-1074.
47. Swedberg M.D., Shannon H.E., Nickel B., Goldberg S.R. D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effects in the rat. J Pharmacol Exp Ther 1992, 263:1015-1022.
48. Tella S.R., Ladenheim B., Cadet J.L. Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 1997, 281:508-513.
49. Tsibulsky V.L., Norman A.B. Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res 1999, 839:85-93.
50. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998, 56:613-672.
51. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007, 12:227-462.
52. Tzschentke T.M., Bruckmann W., Friderichs E. Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci Lett 2002, 329:25-28.
53. Wang Y., Joharchi N., Fletcher P.J., Sellers E.M., Higgins G.A. Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration. Psychopharmacology (Berl) 1995, 120:134-141.
54. Woolverton W.L., Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 2004, 486:251-257.
55. Yanagita T. Drug dependence potential of 1-(m-methoxyphenyl)-2-dimethylaminomethyl)-cyclohexan-1-ol hydrochloride (tramadol) tested in monkeys. Arzneimittelforschung 1978, 28:158-163.